



ELISA Kit for Measuring Human S100A7

CircuLex S100A7/Psoriasin ELISA Kit

Cat# CY-8073

Intended Use..... 1
Storage..... 1
Introduction..... 2
Principle of the Assay..... 2-3
Materials Provided..... 4
Materials Required but not Provided..... 5
Precautions and Recommendations..... 6
Sample Collection and Storage.....7
Detailed Protocol..... 8-9
Calculations..... 10
Measurement Range..... 10
Troubleshooting..... 10
Reagent Stability..... 11
Assay Characteristics..... 11
Example of Test Results.....12
References..... 13
Related Products..... 14

Intended Use

The CycLex Research Product **CircuLex S100A7/Psoriasin ELISA Kit** is used for the quantitative measurement of human S100A7/Psoriasin in washing fluid from skin, nipple fluid, tissue culture medium and other biological samples probably including serum, plasma.

This assay kit is for research use only and not for use in diagnostic or therapeutic procedures.

Storage

- Upon receipt store all components at 4°C.
- Don't expose reagents to excessive light.

Introduction


Human Psoriasin was first identified as an over-expressed secreted protein in psoriatic skin (1). Psoriasin also called S100A7, is distributed in the cytoplasm of keratinocytes in normal human epidermis and is present at the cell periphery in terminally differentiated keratinocytes (2). The peripheral distribution observed in differentiated cells may be important, since, under some conditions, S100A7 may be released from keratinocytes. Several S100 proteins are thought to be secreted (3-5). Indeed, S100A7 has been shown to function as a chemotactic agent and as a cytokine (6, 7), and to attract CD4+ lymphocytes and neutrophils (7). Originally characterized as a marker of psoriasis, S100A7 overexpression is seen in many epidermal inflammatory diseases, including atopic dermatitis, mycosis fungoides, Darier's disease, and inflammatory lichen sclerosus atrophicus (1, 2, 8). The high level of expression in active psoriatic lesions has prompted investigators to suggest that S100A7 may have a chemotactic role in psoriasis (7). S100A7 expression is also increased in invasive skin cancers such as squamous cell carcinoma, and squamous carcinoma in situ, but not in basal cell carcinoma (9).

It should be noted that 11-kD S100A7 protein purified from skin extract preferentially killed the gut bacterium *Escherichia coli*, but had little or no activity against *Staphylococcus aureus* or other bacteria (10). The activity could be inhibited by zinc, but not by other bivalent ions, suggesting that S100A7 kills *E. coli* by sequestration of zinc. Immunohistochemical analysis demonstrated intense expression of S100A7 in healthy skin, particularly in the face, scalp, and sebaceous glands. Real-time PCR and ELISA analysis of keratinocytes stimulated with *E. coli* culture supernatants revealed induced transcription of S100A7 and its secretion. Stimulation with IL-1 beta or, to a lesser extent, with TNF alpha also induced S100A7 transcription and secretion. These results indicated that S100A7 is key to the local innate defense against *E. coli* on body surfaces and kills the bacteria by sequestering essential transition metal ions (10).

Principle of the Assay

The CircuLex S100A7/Psoriasin ELISA Kit employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for human S100A7/Psoriasin has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any human S100A7/Psoriasin present is bound by the immobilized antibody. After washing away any unbound substances, an HRP conjugated antibody specific for human S100A7/Psoriasin is added to the wells. Following a wash to remove any unbound antibody HRP conjugate, the remaining conjugate is allowed to react with the substrate H₂O₂-tetramethylbenzidine. The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured at 450 nm. The absorbance is proportional to the concentration of human S100A7/Psoriasin. A standard curve is constructed by plotting absorbance values versus human S100A7/Psoriasin concentrations of calibrators, and concentrations of unknown samples are determined using this standard curve.

Summary of Procedure



Materials Provided

All samples and standards should be assayed in duplicate. The following components are supplied and are sufficient for the one 96-well microplate kit.

Microplate: One microplate supplied ready to use, with 96 wells (12 strips of 8-wells) in a foil, zip-lock bag with a desiccant pack. Wells are coated with anti-human S100A7/Psoriasis antibody as a capture antibody.

10X Wash Buffer: One 100 mL bottle of 10X buffer containing 2 % Tween®-20

Dilution Buffer: Two bottles containing 20 mL of 1X buffer; use for sample dilution. Ready to use.

Human S100A7/Psoriasis Standard: One vial containing 295.2 ng of lyophilized recombinant human S100A7/Psoriasis

HRP conjugated Detection Antibody: One vial containing 12 mL of HRP (horseradish peroxidase) conjugated anti-human S100A7/Psoriasis antibody. Ready to use.

Substrate Reagent: One bottle containing 20 mL of the chromogenic substrate, tetra-methylbenzidine (TMB). Ready to use

Stop Solution: One bottle containing 20 mL of 1 N H₂SO₄. Ready to use.

Materials Required but not Provided

- **Orbital microplate shaker**
- **Pipettors:** 2-20 μ L, 20-200 μ L and 200-1000 μ L precision pipettors with disposable tips.
- **Precision repeating pipettor**
- **Microcentrifuge and tubes** for sample preparation.
- **Vortex mixer**
- **Microplate washer:** optional (Manual washing is possible but not preferable)
- **Plate reader** capable of measuring absorbance in 96-well plates at dual wavelengths of 450 nm/540 nm. Dual wavelengths of 450/550 or 450/595 nm can also be used. The plate can also be read at a single wavelength of 450 nm, which will give a somewhat higher reading.
- **Software package facilitating data generation and analysis :**optional
- **500 or 1000 mL graduated cylinder**
- **Reagent reservoirs**
- **Deionized water of the highest quality**
- **Disposable paper towels**

Precautions and Recommendations

- **Wear gloves to avoid S100A7/Psoriasis contamination from your skin.**
- Allow all the components to come to room temperature before use.
- All microplate strips that are not immediately required should be returned to the zip-lock pouch, which must be carefully resealed to avoid moisture absorption.
- Do not use kit components beyond the indicated kit expiration date.
- Use only the microtiter wells provided with the kit.
- Rinse all detergent residue from glassware.
- Use deionized water of the highest quality.
- Do not mix reagents from different kits.
- The buffers and reagents in this kit may contain preservatives or other chemicals. Care should be taken to avoid direct contact with these reagents.
- Do not mouth pipette or ingest any of the reagents.
- Do not smoke, eat, or drink when performing the assay or in areas where samples or reagents are handled.
- Dispose of tetra-methylbenzidine (TMB) containing solutions in compliance with local regulations.
- Avoid contact with the acidic Stop Solution and Substrate Solution, which contains hydrogen peroxide.
- Wear gloves and eye protection when handling immunodiagnostic materials and samples of rat origin, and these reagents. In case of contact with the Stop Solution and the Substrate Solution, wash skin thoroughly with water and seek medical attention, when necessary.
- **Biological samples might be contaminated with infectious agents. Do not ingest, expose to open wounds or breathe aerosols. Wear protective gloves and dispose of biological samples properly.**
- **CAUTION: Sulfuric Acid is a strong acid. Wear disposable gloves and eye protection when handling Stop Solution.**

Sample Collection and Storage

Washing fluid from skin: Rinse 0.5 cm² area of various body skin with 250 µL of 10 mM sodium phosphate buffer, pH 7.4. according to Glaser, R et al. (10). Remove any particulates by centrifugation and assay immediately or aliquot and store samples at below -70°C. Avoid repeated freeze-thaw cycles.

Serum: Allow blood samples to clot for 60 ± 30 minutes. Centrifuge the samples at 4°C for 10 minutes at 1,000 x g. Remove serum and assay immediately or store samples on ice for up to 6 hours before assaying. Aliquots of serum may also be stored at below -70°C for extended periods of time. Avoid repeated freeze-thaw cycles.

Plasma: Collect plasma using EDTA-Na₂ as the anticoagulant. If possible, collect the plasma into a mixture of EDTA-Na₂ and Futhan5 to stabilize the sample against spontaneous *in vitro* complement activation. Immediately centrifuge samples at 4°C for 15 minutes at 1,000 x g. Assay immediately or store samples on ice for up to 6 hours before assaying. Aliquots of plasma may also be stored at below -70°C for extended periods of time. Avoid repeated freeze-thaw cycles.

Note: Citrate plasma has not been validated for use in this assay.

Other biological samples: Remove any particulates by centrifugation and assay immediately or aliquot and store samples at below -70°C. Avoid repeated freeze-thaw cycles.

Detailed Protocol

The CycLex Research Product **CircuLex S100A7/Psoriasis ELISA Kit** is provided with removable strips of wells so the assay can be carried out on separate occasions using only the number of strips required for the particular determination. Since experimental conditions may vary, an aliquot of the Human S100A7/Psoriasis Standard within the kit, should be included in each assay as a calibrator. Disposable pipette tips and reagent troughs should be used for all liquid transfers to avoid cross-contamination of reagents or samples.

Preparation of Working Solutions

All reagents need to be brought to room temperature prior to the assay. Assay reagents are supplied ready-to-use, with the exception of **10X Wash Buffer** and **Human S100A7/Psoriasis Standard**.

1. Prepare a working solution of Wash Buffer by adding 100 mL of the **10X Wash Buffer** to 900 mL of deionized (distilled) water. Mix well. Store at 4°C for two weeks or -20°C for long-term storage.
2. Reconstitute **Human S100A7/Psoriasis Standard** with **0.82 mL** of **Dilution Buffer**. The concentration of the human S100A7/Psoriasis in vial should be **360 ng/mL**, which is referred as a **Master Standard** of human S100A7/Psoriasis.

Prepare Standard Solutions as follows:

Use the **Master Standard** to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The 90 ng/mL standard (Std.1) serves as the highest standard. The **Dilution Buffer** serves as the zero standard (Blank).

	Volume of Standard	Dilution Buffer	Concentration
Std.1	150 µL of Master Standard	450 µL	90.00 ng/mL
Std.2	200 µL of Std. 1 (90.00 ng/ml)	400 µL	30.00 ng/mL
Std.3	200 µL of Std. 2 (30.00 ng/ml)	400 µL	10.00 ng/mL
Std.4	200 µL of Std. 3 (10.00 ng/ml)	400 µL	3.33 ng/mL
Std.5	200 µL of Std. 4 (3.33 ng/ml)	400 µL	1.11 ng/mL
Std.6	200 µL of Std. 5 (1.11 ng/ml)	400 µL	0.37 ng/mL
Std.7	200 µL of Std. 6 (0.37 ng/ml)	400 µL	0.12 ng/mL
Blank	-	300 µL	0 ng/mL

Note: Do not use a Repeating pipette. Change tips for every dilution. Wet tip with Dilution Buffer before dispensing. Unused portions of Standards should be aliquoted and stored at below -70°C immediately. Avoid multiple freeze and thaw cycles.

Sample Preparation

- Washing fluids from skin require neat.
- Other biological samples require neat to a 5-fold dilution.
e.g. 50 µL of sample + 200 µL of Dilution Buffer

Assay Procedure

1. Remove the appropriate number of microtiter wells from the foil pouch and place them into the well holder. Return any unused wells to the foil pouch, refold, seal with tape and store at 4°C.
2. Dilute samples with Dilution Buffer if necessary. (See "Sample Preparation" above.)
3. Pipette **100 µL** of **Standard Solutions (Std1-Std7, Blank)** and (diluted) **samples** in duplicates, into the appropriate wells.
4. Incubate the plate **at room temperature (ca.25°C) for 1 hour, shaking at ca. 300 rpm on an orbital microplate shaker.**
5. Wash 4-times by filling each well with Wash Buffer (350 µL) using a squirt bottle, multi-channel pipette, manifold dispenser or microplate washer*.
6. Add **100 µL** of **HRP conjugated Detection Antibody** into each well.
7. Incubate the plate **at room temperature (ca.25°C) for 1 hour, shaking at ca. 300 rpm on an orbital microplate shaker.**
8. Wash 4-times by filling each well with Wash Buffer (350 µL) using a squirt bottle, multi-channel pipette, manifold dispenser or microplate washer*.
9. Add **100 µL** of **Substrate Reagent**. Avoid exposing the microtiter plate to direct sunlight. Covering the plate with e.g. aluminum foil is recommended. Return Substrate Reagent to 4°C immediately after the necessary volume is removed
10. Incubate the plate **at room temperature (ca. 25°C) for 10-20 minutes, shaking at ca. 300 rpm on an orbital microplate shaker.** The incubation time may be extended up to 30 minutes if the reaction temperature is below than 20°C.
11. Add **100 µL** of **Stop Solution** to each well in the same order as the previously added Substrate Reagent.
12. Measure absorbance in each well using a spectrophotometric microplate reader at dual wavelengths of 450/540 nm. Dual wavelengths of 450/550 or 450/595 nm can also be used. Read the microplate at 450 nm if only a single wavelength can be used. Wells must be read within 30 minutes of adding the Stop Solution*.

Note-1: Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.

Note-2: Reliable standard curves are obtained when either O.D. values do not exceed 0.2 units for the blank (zero concentration), or 2.8 units for the highest standard concentration. The plate should be monitored at 5-minute intervals for approximately 30 minutes.

Note-3: If the microplate reader is not capable of reading absorbance greater than the absorbance of the highest standard, perform a second reading at 405 nm. A new standard curve, constructed using the values measured at 405 nm, is used to determine human S100A7/Psoriasin concentration of off-scale samples. The readings at 405 nm should not replace the on-scale readings at 450 nm.

Calculations

Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density. Plot the optical density for the standards versus the concentration of the standards and draw the best curve. To determine the human S100A7/Psoriasis concentration of each sample, first find the absorbance value on the y-axis and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the x-axis and read the corresponding human S100A7/Psoriasis concentration. If the samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

- A. The dose-response curve of this assay fits best to a sigmoidal 5-parameter logistic equation. The results of unknown samples can be calculated with any computer program having a 5-parameter logistic function. It is important to make an appropriate mathematical adjustment to accommodate for the dilution factor.
- B. Most microtiter plate readers perform automatic calculations of analyte concentration. The calibration curve is constructed by plotting the absorbance (Y) of calibrators versus log of the known concentration (X) of calibrators, using the four-parameter function. Alternatively, the logit log function can be used to linearize the calibration curve (i.e. logit of absorbance (Y) is plotted versus log of the known concentration (X) of calibrators).

Measurement Range

The measurement range is 0.12 ng/mL to 90 ng/mL. Any sample reading higher than the highest standard should be diluted with Dilution Buffer in higher dilution and re-assayed. Dilution factors need to be taken into consideration in calculating the human S100A7/Psoriasis concentration.

Troubleshooting

1. The Human S100A7 Standard should be run in duplicate, using the protocol described in the **Detailed Protocol**. Incubation times or temperatures significantly different from those specified may give erroneous results.
2. Poor duplicates, accompanied by elevated values for wells containing no sample, indicate insufficient washing. If all instructions in the **Detailed Protocol** were followed accurately, such results indicate a need for washer maintenance.
3. Overall low signal may indicate that desiccation of the plate has occurred between the final wash and addition of Substrate Reagent. Do not allow the plate to dry out. Add Substrate Reagent immediately after wash.

Reagent Stability

All of the reagents included in the CycLex Research Product **CircuLex S100A7/Psoriasis ELISA Kit** have been tested for stability. Reagents should not be used beyond the stated expiration date. Upon receipt, kit reagents should be stored at 4°C, except the reconstituted Human S100A7 Standard must be stored at below -70°C. Coated assay plates should be stored in the original foil bag sealed by the zip lock and containing a desiccant pack.

For Research Use Only, Not For Use in Diagnostic or Therapeutic procedures


Assay Characteristics

1. Sensitivity

The limit of detection (defined as such a concentration of human S100A7/Psoriasis giving absorbance higher than mean absorbance of blank* plus three standard deviations of the absorbance of blank: A blank + 3*SD blank) is better than 0.12 ng/ml of sample.

* Dilution Buffer is pipetted into blank wells

Typical standard curve of human S100A7/Psoriasis ELISA



2. Precision

Intra-assay Precision (Precision within an assay)

Three samples of known concentration were tested fourteen times on one plate to assess intra-assay precision.

- Intra-assay (Within-Run, n=14) CV=5.8, 9.2, 4.3 %

S100A7 conc. (ng/ml)			
	Sample 1	Sample 2	Sample 3
1	32.79	17.15	6.11
2	32.38	16.78	6.04
3	35.78	17.71	5.86
4	29.96	18.78	6.04
5	29.70	16.37	6.10
6	29.69	15.93	6.00
7	31.25	15.55	5.86
8	28.17	19.03	5.59
9	31.58	21.38	6.53
10	31.46	18.91	5.73
11	31.81	19.43	6.19
12	31.44	16.36	6.01
13	32.81	17.75	6.53
14	30.85	16.60	6.06
MAX.	35.78	21.38	6.53
MIN.	28.17	15.55	5.59
MEAN	31.40	17.69	6.05
S.D.	1.82	1.63	0.26
C.V.	5.8%	9.2%	4.3%

Attention : Wear gloves to avoid S100A7/Psoriasin contamination from your skin.

Example of Test Results

Fig.1 S100A7 level of washing fluids from several parts of human skin, urine and saliva





Fig.2 S100A7 level in culture supernatants of several cell lines



References

1. Madsen P, Rasmussen HH & Leffers H et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. *J Invest Dermatol* (1991) **97**: 701–712.
2. Broome AM, Ryan D & Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. *J Histochem Cytochem* (2003) **51**: 675–685.
3. Hitomi J, Yamaguchi K & Kikuchi Y et al. A novel calcium-binding protein in amniotic fluid, CAAF1: Its molecular cloning and tissue distribution. *J Cell Sci* (1996) **109**: 805–815.
4. Katz AB & Taichman LB. A partial catalog of proteins secreted by epidermal keratinocytes in culture. *J Invest Dermatol* (1999) **112**: 818–821.
5. Karimi-Busheri F, Marcoux Y & Tredget EE et al. Expression of a releasable form of annexin II by human keratinocytes. *J Cell Biochem* (2002) **86**: 737–747.
6. Hoffmann HJ, Olsen E & Etzerodt M et al. Psoriasin binds calcium and is upregulated by calcium to levels that resemble those observed in normal skin. *J Invest Dermatol* (1994) **103**: 370–375.
7. Jinquan T, Vorum H & Larsen CG et al. Psoriasin: A novel chemotactic protein. *J Invest Dermatol* (1996) **107**: 5–10.
8. Algermissen B, Sitzmann J, LeMotte P & Czarnetzki B. Differential expression of CRABP II, psoriasin and cytokeratin 1 mRNA in human skin diseases. *Arch Dermatol Res* (1996) **288**: 426–430.
9. Alowami S, Qing G & Emberley E et al. Psoriasin (S100A7) expression is altered during skin tumorigenesis. *BMC Dermatol* (2003) **3**: 1.
10. Glaser, R.; Harder, J.; Lange, H.; Bartels, J.; Christophers, E.; Schroder, J.-M. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. *Nature Immun.* (2005) **6**: 57-64

Related Products

- * CircuLex S100A13 ELISA Kit: Cat# CY-8057
- * CircuLex S100A12 ELISA Kit: Cat# CY-8058
- * CircuLex S100P ELISA Kit: Cat# CY-8060
- * CircuLex S100A8-MRP8 ELISA Kit: Cat# CY-8061
- * CircuLex S100A9-MRP14 ELISA Kit: Cat# CY-8062
- * CircuLex S100A11 ELISA Kit: Cat# CY-8063
- * CircuLex S100A14 ELISA Kit: Cat# CY-8064
- * CircuLex S100A7/Psoriasin ELISA Kit: Cat# CY-8073
- * CircuLex S100A4 ELISA Kit Ver.2: Cat# CY-8086

- * Anti-Human S100A3 (Clone YK-3E3): Cat# CY-M1039
- * Anti-Human S100A4 (p9Ka): Cat# CY-P1026
- * Anti-Human S100P: Cat# CY-P1028
- * Anti-Human S100A10: Cat# CY-P1033

- * **Anti-Human S100A16: Cat# CY-P1034**
- * **Anti-Human S100A3: Cat# CY-P1039**
- * **Anti-Human S100A2: Cat# CY-P1040**

- * **Human S100B: Cat# CY-R2250**
- * **Human S100A1: Cat# CY-R2251**
- * **Human S100A2: Cat# CY-R2252**
- * **Human S100A3: Cat# CY-R2253**
- * **Human S100A4: Cat# CY-R2254**
- * **Human S100A5: Cat# CY-R2255**
- * **Human S100A6: Cat# CY-R2256**
- * **Human S100A7: Cat# CY-R2257**
- * **Human S100A8: Cat# CY-R2258**
- * **Human S100A9: Cat# CY-R2259-G**
- * **Human S100A9: Cat# CY-R2259-H**
- * **Human S100A10: Cat# CY-R2260**
- * **Human S100A12: Cat# CY-R2262-G**
- * **Human S100A12: Cat# CY-R2262-H**
- * **Human S100A13: Cat# CY-R2263**
- * **Human S100A14: Cat# CY-R2264**
- * **Human S100A16: Cat# CY-R2266**
- * **Human S100P: Cat# CY-R2267**
- * **Human S100A11: Cat# CY-R2269**

- * **Human S100A1 Low Endotoxin: Cat# CY-R2451**
- * **Human S100A3 Low Endotoxin: Cat# CY-R2453**
- * **Human S100A4 Low Endotoxin: Cat# CY-R2454**
- * **Human S100A7 Low Endotoxin: Cat# CY-R2457**
- * **Human S100A8 Low Endotoxin: Cat# CY-R2458**
- * **Human S100A9 Low Endotoxin: Cat# CY-R2459-G**
- * **Human S100A11 Low Endotoxin: Cat# CY-R2461**
- * **Human S100A12 Low Endotoxin: Cat# CY-R2462-G**
- * **Human S100A14 Low Endotoxin: Cat# CY-R2464**
- * **Human S100P Low Endotoxin: Cat# CY-R2467**

PRODUCED BY

CycLex Co., Ltd.
1063-103 Terasawaoka
Ina, Nagano 396-0002
Japan
Fax: +81-265-76-7618
e-mail: info@cyclex.co.jp
URL: <http://www.cyclex.co.jp>

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from CycLex Co., Ltd.. To inquire about licensing for such commercial use, please contact us via email.